Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Fractures of the trapezium occur infrequently, accounting for only 3.5 % of all carpal fractures. Trapezium fractures with concomitant Bennett's fracture-dislocations are exceedingly rare without a consensus on treatment recommendations. Here, we present a case of a simultaneous Bennett's fracture with a trapezium fracture in a pediatric patient. Our patient was treated with open reduction and internal fixation. Clinically, the patient was pain free with range of motion comparable to his uninjured side and without joint instability. A review of the literature reveals only twelve other cases reported in adult patients all of which were male with an average age of twenty-eight at the time of injury. Open reduction is the most popular treatment approach, but closed reduction can also be utilized with success in these injuries. While there is a large degree of heterogeneity of outcome reporting methodology, most patients have satisfactory outcomes and return to function comparable to their contralateral side.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391421 | PMC |
| http://dx.doi.org/10.1016/j.jpra.2025.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concomitant Bennett's fracture-dislocation with a trapezium fracture: A case report and review of the literature.
JPRAS Open
September 2025
Division of Plastic Surgery, Michigan State University, Corewell Health, 275 Michigan Street NE, Grand Rapids, MI, 49503, USA.
Fractures of the trapezium occur infrequently, accounting for only 3.5 % of all carpal fractures. Trapezium fractures with concomitant Bennett's fracture-dislocations are exceedingly rare without a consensus on treatment recommendations.
View Article and Find Full Text PDFEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
EClinicalMedicine
July 2025
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) slow progression of chronic kidney disease (CKD) but there is no randomised evidence of their effects on health-related quality of life (QoL) and healthcare use. We explored the effects of empagliflozin on health-related QoL, healthcare use and UK healthcare costs in the EMPA-KIDNEY trial.
Methods: EMPA-KIDNEY, a randomised, double blind, placebo-controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included participants aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to <45 mL/min/1.
A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma.
bioRxiv
June 2025
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Uveal melanoma (UM) is a highly aggressive intraocular malignancy with limited therapeutic options for metastatic disease. Existing transgenic UM mouse models inadequately recapitulate human disease progression, while transplant models lack immune competence for studying the tumor immune microenvironment and therapeutic interventions. To address these limitations, we developed a genetically engineered mouse model incorporating stepwise genetic alterations implicated in human UM progression.
View Article and Find Full Text PDFAnalysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data.
Mult Scler Relat Disord
July 2025
Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-chōme-1-1 Ogawahigashichō, Kodaira, Tokyo, 187-8551, Japan.
Satralizumab showed a comparable safety profile versus placebo in 2 pivotal neuromyelitis optica spectrum disorder (NMOSD) studies. We analyzed infection rates with long-term satralizumab treatment in the open-label study, SAkuraMoon, and in a post-marketing setting (PMS), comparing frequencies with US-based health claims real-world data (US-RWD). Incidence rates of infection per 100 patient-years (IR/100 PY) were analyzed in the SAkura studies (clinical cut-off date: 31 January 2023).
View Article and Find Full Text PDFArticle Synopsis
- Chromatin structure is crucial for DNA accessibility and gene expression; disrupting it can lead to diseases and cancer.
- H2B variants, which are slightly different from standard H2B histones, have been found to be dysregulated during processes like epithelial to mesenchymal transition and could function as "oncohistones," similar to other histone mutations linked to cancer.
- Research indicates that these H2B variants modify chromatin dynamics and can affect oncogenic gene expression, suggesting they could serve as early cancer biomarkers and potential therapeutic targets.